Overview

PE0116 Injection in Treatment of Patients With Advanced Solid Tumours

Status:
Active, not recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai HyaMab Biotech Co.,Ltd.